Morepen Labs.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE083A01026
  • NSEID: MOREPENLAB
  • BSEID: 500288
INR
52.37
2.21 (4.41%)
BSENSE

Jun 15, 03:30 PM

BSE+NSE Vol: 2.54 cr

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Venus Remedies
Kwality Pharma
Novartis India
Morepen Labs.
Panacea Biotec
Solara Active
Unichem Labs.
Hikal
Dishman Carbogen
Indoco Remedies
Sai Parenteral's

Why is Morepen Laboratories Ltd ?

1
Poor long term growth as Net Sales has grown by an annual rate of 8.73% and Operating profit at 0.22% over the last 5 years
2
Negative results in Mar 26
  • PBT LESS OI(Q) At Rs 14.83 cr has Fallen at -24.9% (vs previous 4Q average)
  • ROCE(HY) Lowest at 7.60%
  • PAT(Q) At Rs 15.74 cr has Fallen at -17.4% (vs previous 4Q average)
3
With ROE of 5.7, it has a Expensive valuation with a 2.2 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -18.88%, its profits have fallen by -39.3%
4
Despite the size of the company, domestic mutual funds hold only 0% of the company
  • Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
5
Underperformed the market in the last 1 year
  • Even though the market (BSE500) generated negative returns of -0.51% in the last 1 year, its fall in the stock was much higher with a return of -18.88%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Morepen Labs. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Morepen Labs.
-18.88%
-0.43
43.51%
Sensex
-5.98%
-0.45
13.24%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
8.73%
EBIT Growth (5y)
0.22%
EBIT to Interest (avg)
13.59
Debt to EBITDA (avg)
0.49
Net Debt to Equity (avg)
0.09
Sales to Capital Employed (avg)
1.84
Tax Ratio
20.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.85%
ROCE (avg)
13.03%
ROE (avg)
10.00%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
40
Industry P/E
34
Price to Book Value
2.30
EV to EBIT
33.47
EV to EBITDA
23.76
EV to Capital Employed
2.19
EV to Sales
1.65
PEG Ratio
NA
Dividend Yield
0.38%
ROCE (Latest)
6.55%
ROE (Latest)
5.75%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company
CASH AND CASH EQUIVALENTS(HY)

Highest at Rs 68.83 cr

NET SALES(Q)

Highest at Rs 484.72 cr

-15What is not working for the Company
PBT LESS OI(Q)

At Rs 14.83 cr has Fallen at -24.9% (vs previous 4Q average

ROCE(HY)

Lowest at 7.60%

PAT(Q)

At Rs 15.74 cr has Fallen at -17.4% (vs previous 4Q average

OPERATING PROFIT TO NET SALES (Q)

Lowest at 5.04%

NON-OPERATING INCOME(Q)

is 36.32 % of Profit Before Tax (PBT

Loading Valuation Snapshot...

Here's what is working for Morepen Labs.

Net Sales - Quarterly
Highest at Rs 484.72 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Cash and Cash Equivalents - Half Yearly
Highest at Rs 68.83 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Morepen Labs.

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 14.83 cr has Fallen at -24.9% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 19.76 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 15.74 cr has Fallen at -17.4% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 19.06 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Operating Profit Margin - Quarterly
Lowest at 5.04%
in the last five quarters
MOJO Watch
Company's efficiency has deteriorated

Operating Profit to Sales

Non Operating Income - Quarterly
is 36.32 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT

Non Operating Income - Quarterly
Highest at Rs 8.46 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income